Skip to content

Comparison of Analgesic Efficacy Between Liposomal Bupivacaine and Ropivacaine Combined with Dexamethasone via Serratus Anterior Plane Block in Patients Undergoing Uniportal Video-Assisted Thoracoscopic Lobectomy

Comparison of Analgesic Efficacy Between Liposomal Bupivacaine and Ropivacaine Combined with Dexamethasone via Serratus Anterior Plane Block in Patients Undergoing Uniportal Video-Assisted Thoracoscopic Lobectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122550
Enrollment
Unknown
Registered
2026-04-15
Start date
2025-06-08
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Test group 1:0.3325% liposomal bupivacaine injection with a total volume of 25 mL was administered for ultrasound-guided serratus anterior plane block (SAPB).
Control group:Ultrasound-guided serratus anterior plane block (SAPB) was performed using a 0.5% ropivacaine mixed solution containing 4 mg dexamethasone at a total volume of 25 mL.

Sponsors

Lishui People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients of either sex, aged 18 to 65 years, with a body mass index (BMI) ranging from 20 to 30 kg/m²; 2. American Society of Anesthesiologists (ASA) physical status classification Grade ? or ?; 3. Patients scheduled for elective uniportal video-assisted thoracoscopic lobectomy; 4. Patients who have signed the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity to the local anesthetics used in this study (bupivacaine, ropivacaine); 2. Regular opioid use within the past 3 months or a history of substance abuse; 3. A history of chronic pain requiring long-term medication; 4. A history of previous ipsilateral thoracic surgery or trauma; 5. Intolerance to non-steroidal anti-inflammatory drugs (NSAIDs), active gastric ulcer, abnormal coagulation function, or severe hepatic or renal insufficiency; 6. Severe cardio-cerebrovascular diseases, uncontrolled hypertension, epilepsy, psychiatric disorders, pregnancy or lactation; 7. Communication disorders, cognitive dysfunction, or any other condition that renders the patient unable to cooperate with pain scale assessments and study follow-up; 8. Emergency surgery, intraoperative conversion to thoracotomy, or the presence of contraindications to serratus anterior plane block (SAPB) (e.g., infection at the puncture site, patient refusal).

Design outcomes

Primary

MeasureTime frame
Morphine milligram equivalents of opioid consumption postoperatively;

Secondary

MeasureTime frame
Opioid consumption;Numeric Rating Scale (NRS) pain scores at rest ;Time to first PCA pump activation;Postoperative quality of recovery (15-item Quality of Recovery Scale, QoR-15);Incidence of adverse events (AEs);Incidence of chronic pain at 3 months postoperatively;NRS score on movement (during deep breathing);Rescue analgesic consumption;Postoperative length of hospital stay;Time to first postoperative ambulation;Incidence of postoperative pulmonary complications;Mean arterial pressure;Heart rate;

Countries

China

Contacts

Public ContactDong Xiaoli

Lishui People's Hospital, Lishui, Zhejiang 323000, China

1192159768@qq.com+86 189 5709 3880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026